Key Facts
- CAS
- 920014-72-8
- Molecular Weight (MW)
- 1117.3 g/mol
- Half-life
- ~11 hours
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Once daily
- Last updated
- 12/14/2025
- Targets
- MC4R (melanocortin-4 receptor)HypothalamusCentral nervous system
Overview
—
Protocol
- Dosage Range
- Titrated from 1 mg to 2-3 mg daily based on response
- Frequency
- Once daily
- Cycle
- Long-term use as prescribed
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Reconstitute with sterile water for injection per package insert
Science
Mechanism of Action
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist that activates the MC4R pathway in the brain, which plays a key role in regulating hunger, energy expenditure, and body weight. It is specifically indicated for rare genetic obesity disorders.
Targets
MC4R (melanocortin-4 receptor)HypothalamusCentral nervous system
Studies
- Setmelanotide for POMC, PCSK1, and LEPR deficiency obesity— Journal/year not available
Benefits
Significant weight loss in genetic obesity disordersReduced hungerImproved quality of lifeTreatment for rare genetic obesity syndromes
Potential Side Effects
- Injection site hyperpigmentation
- Nausea
- Injection site reactions
- Diarrhea
- Abdominal pain
- Vomiting
- Depression
- Suicidal ideation
- Skin hyperpigmentation
References
- FDA Label - ImcivreeExternal link · Year —